Edwards Lifesciences Corp (EW) VP Donald E. Bobo, Jr. Sells 75 Shares of Stock

Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 75 shares of the stock in a transaction on Friday, August 31st. The stock was sold at an average price of $144.24, for a total transaction of $10,818.00. Following the completion of the sale, the vice president now owns 19,990 shares in the company, valued at approximately $2,883,357.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Wednesday, July 11th, Donald E. Bobo, Jr. sold 5,500 shares of Edwards Lifesciences stock. The stock was sold at an average price of $145.57, for a total transaction of $800,635.00.

NYSE EW traded up $0.44 during mid-day trading on Thursday, reaching $140.24. 19,051 shares of the stock were exchanged, compared to its average volume of 980,069. Edwards Lifesciences Corp has a 1 year low of $100.20 and a 1 year high of $156.87. The company has a market capitalization of $30.20 billion, a PE ratio of 36.68, a price-to-earnings-growth ratio of 2.10 and a beta of 0.57. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.86.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million for the quarter, compared to the consensus estimate of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the firm posted $1.08 earnings per share. equities analysts expect that Edwards Lifesciences Corp will post 4.67 EPS for the current year.

A number of analysts recently issued reports on EW shares. Guggenheim reissued a “buy” rating and set a $170.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. ValuEngine downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, June 6th. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. Northland Securities reissued a “hold” rating and set a $120.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Finally, Citigroup increased their price target on shares of Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. Edwards Lifesciences presently has a consensus rating of “Buy” and an average price target of $152.45.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Global X Management Co. LLC lifted its stake in shares of Edwards Lifesciences by 13.3% in the first quarter. Global X Management Co. LLC now owns 9,985 shares of the medical research company’s stock worth $1,393,000 after buying an additional 1,176 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Edwards Lifesciences by 9.1% in the first quarter. Daiwa Securities Group Inc. now owns 6,891 shares of the medical research company’s stock worth $961,000 after buying an additional 572 shares in the last quarter. Atria Investments LLC lifted its stake in shares of Edwards Lifesciences by 18.9% in the first quarter. Atria Investments LLC now owns 4,287 shares of the medical research company’s stock worth $598,000 after buying an additional 680 shares in the last quarter. Zeke Capital Advisors LLC lifted its stake in shares of Edwards Lifesciences by 133.7% in the first quarter. Zeke Capital Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $614,000 after buying an additional 2,516 shares in the last quarter. Finally, Mackay Shields LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $4,970,000. 82.12% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Story: How Short Selling Works

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply